Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.40 |
| ▸ | SLC9A5 | Q14940 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 9/20 | 0.31 |
| ▸ | PPARA | Q07869 | 9/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400922 | 0.81 | NUDT1 (0.40) | NUDT1SLC9A5MAPK1PDE2APDE5A | |
| SCHEMBL21780699 | 0.67 | NUDT1 (0.42) | NUDT1MAPK1PDE4BPDE4DPDE10A | |
| SCHEMBL1998973 | 0.65 | SLC9A5 (0.37) | SLC9A5PDE2APDE5APDE1BPDE4B | |
| SCHEMBL4380411 | 0.62 | MEN1 (0.35) | SLC9A5MAPK1HSD17B10POLBMKNK1 | |
| SCHEMBL8597404 | 0.61 | — | — | |
| SCHEMBL13634391 | 0.59 | NOS1 (0.34) | MAPK1HSD17B10 | |
| SCHEMBL31243237 | 0.59 | ALDH1A1 (0.42) | HSD17B10 | |
| SCHEMBL31243236 | 0.59 | ALDH1A1 (0.42) | HSD17B10 | |
| SCHEMBL1723682 | 0.59 | ALDH1A1 (0.42) | HSD17B10 | |
| SCHEMBL2535002 | 0.58 | EGFR (0.35) | POLBMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906653-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | CANTIN LOUIS-DAVID | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | NUDT1 529/4885SLC9A5 2276/4885MAPK1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.